Search review questions

Adverse effects · people with acute hordeolum

Resolution of hordeolum between 8 and 30 days after diagnosis, or that closest to 14 days after diagnosis · people with acute hordeolum

Participants who required surgical incision and drainage after the treatment period or seven days after diagnosis · people with acute hordeolum

Participants experiencing the occurrence of a chalazion after the treatment period or seven days after diagnosis · people with acute hordeolum

Participants experiencing the recurrence of a hordeolum within six months and one year · people with acute hordeolum

Resolution of hordeolum between 8 and 30 days after diagnosis, or that closest to 14 days after diagnosis · people with acute hordeolum

Participants with a secondary hordeolum during or after the treatment period and seven days after diagnosis · people with acute hordeolum

Adverse effects · people with acute hordeolum

Resolution of hordeolum between 8 and 30 days after diagnosis, or that closest to 14 days after diagnosis · people with acute hordeolum

Participants who required surgical incision and drainage after the treatment period or seven days after diagnosis · people with acute hordeolum

Participants experiencing the occurrence of a chalazion after the treatment period or seven days after diagnosis · people with acute hordeolum

Participants experiencing the recurrence of a hordeolum within six months and one year · people with acute hordeolum

Participants with a secondary hordeolum during or after the treatment period and seven days after diagnosis · people with acute hordeolum

Participants who required surgical incision and drainage after the treatment period or seven days after diagnosis · people with acute hordeolum

Participants experiencing the occurrence of a chalazion after the treatment period or seven days after diagnosis · people with acute hordeolum

Participants experiencing the recurrence of a hordeolum within six months and one year · people with acute hordeolum

Participants with a secondary hordeolum during or after the treatment period and seven days after diagnosis · people with acute hordeolum

Adverse effects · people with acute hordeolum

Resolution of hordeolum between 8 and 30 days after diagnosis, or that closest to 14 days after diagnosis · people with acute hordeolum

Proportion of participants who lost two or more lines of best‐corrected visual acuity (BCVA) · participants aged 18‐60 years with myopia ranging in severity up to 12 diopters (D)

Postoperative pain score: 1 year · participants aged 18‐60 years with myopia ranging in severity up to 12 diopters (D)

Proportion of participants requiring secondary procedures · children with congenital nasolacrimal duct obstruction (NLDO)

Complications · children with congenital nasolacrimal duct obstruction (NLDO)

Change in the prevalence of cataract blindness · people with vision impairment caused by cataract

Service utilisation: uptake of referral · people with vision impairment caused by cataract

Cataract Surgical Coverage · people with vision impairment caused by cataract

Surgical outcome (visual acuity in the operated eye) · people with vision impairment caused by cataract

Adverse events · people with vision impairment caused by cataract

Prevalence of visual impairment due to cataract · people with vision impairment caused by cataract

Cataract Surgical Coverage · people with vision impairment caused by cataract

Surgical outcome (visual acuity in the operated eye) · people with vision impairment caused by cataract

Adverse events · people with vision impairment caused by cataract

Change in the prevalence of cataract blindness · people with vision impairment caused by cataract

Prevalence of visual impairment due to cataract · people with vision impairment caused by cataract

Elimination of all clinical signs of ocular surface inflammation ('complete success'), preferably measured by a composite grading system, at three months (± one month) after start of treatment · children with blepharokeratoconjunctivitis

Uncontrolled or poorly controlled disease progression due to treatment failure, at three months (± one month) after start of treatment · children with blepharokeratoconjunctivitis

Quality of life · children with blepharokeratoconjunctivitis

Size of lesion · People with toxoplasma retinochoroiditis

Quality of life · participants with corneal abrasion

Quality of life at 3 months after surgery · people having cataract surgery

Poor vision outcome due to MO at 3 months after surgery · people having cataract surgery

Poor vision outcome due to MO at 12 months after surgery · people having cataract surgery

Adverse outcomes · People with HED who had corneal graft(s)

Quality of life · People with HED who had corneal graft(s)

Comparison (Intervention vs. comparator) · people with dry eye

Clinical improvement (non‐recurrence risk) · people with primary or recurrent pterygium

Need for repeat surgery · people with primary or recurrent pterygium

Mean change in visual acuity · people with primary or recurrent pterygium

Quality of life · people with primary or recurrent pterygium

Direct and indirect costs · people with primary or recurrent pterygium